Israeli pharma-tech company Syqe Medical recently conducted a clinical trial in which they found evidence that inhaling “extremely low and precise doses” of tetrahydrocannabinol (THC) – the principal psychoactive component in cannabis products – can be used as an effective pain reliever while avoiding the “common [psychoactive] side effects” normally associated with cannabis use.The research team published their findings in the European Journal of Pain, providing the scientific community with the first research-based evidence that microdosing – “the process of using extremely low doses of active drug compounds to treat various conditions” – can actually be applied to medical cannabis solutions.”The study shows that an optimally effective dose to relieve pain is just 500 micrograms of THC. Syqe patients consume 3-4 inhalations per day, each up to 500 micrograms,” according to a statement by the Israeli investment platform OurCrowd. “A typical medical cannabis patient consumes 1 gram of 15% THC cannabis per day, which contains 150,000 micrograms of THC. This illustrates a key finding from the study that patients can benefit from dramatically lower doses.”The Syqe Selective-Dose Inhaler, marketed by Israeli pharmaceutical giant Teva, is the world’s first marijuana inhaler capable of delivering botanicals with the same level of safety and precision as conventional drugs. It is “presumed” that the Syqe platform’s bioavailability-enhancing technologies and selective… Source: https://mmpconnect.com/israeli-researchers-provide-evidence-microdosing-cannabis-relieves-pain/